Hybrid compounds as new Bcr/Abl inhibitors

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) are driven by the Bcr/Abl oncoprotein.
• Targeting Bcr/Abl kinase activity is a validated therapeutic strategy for these leukemias.
• Existing therapies like imatinib, nilotinib, and dasatinib have revolutionized CML treatment but resistance can emerge.

Purpose of the Study:

• To design and synthesize novel 2,4-disubstituted thiazole derivatives as potential Bcr/Abl kinase inhibitors.
• To evaluate the inhibitory activity of these compounds against Bcr/Abl kinase.
• To assess the efficacy of these compounds in inhibiting the proliferation of leukemia cancer cells.

Main Methods:

• Hybridization of structural features from FDA-approved drugs (imatinib, nilotinib, dasatinib) to create new thiazole scaffolds.
• Synthesis of a series of 2,4-disubstituted thiazole derivatives.
• Biochemical kinase assays to measure Bcr/Abl inhibition.
• Cell proliferation assays using K562 and KU812 leukemia cell lines.

Main Results:

• The synthesized thiazole derivatives demonstrated significant suppression of Bcr/Abl kinase activity.
• These compounds effectively inhibited the proliferation of K562 and KU812 leukemia cells.
• Compound 4i exhibited inhibitory potency comparable to nilotinib in both biochemical and cellular assays.

Conclusions:

• The novel 2,4-disubstituted thiazole derivatives are potent Bcr/Abl inhibitors.
• Compound 4i represents a promising lead compound with potential for further development.
• These findings suggest a viable strategy for developing new anticancer drugs targeting Bcr/Abl kinase.